Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity

American Journal of Medicine

Volumn 116, Issue 5, 2004, Pages 325-331

  Sin, Donald D ^a,b   Golmohammadi, Kamran ^a   Jacobs, Philip ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; MONTE CARLO METHOD; MORTALITY; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 1242315575     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.027     Document Type: Article

References (35)

1. Hurd S. The impact of COPD on lung health worldwide epidemiology and incidence . Chest. 117:(suppl 2):2000;1-4.
2. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020 Global Burden of Disease Study . Lancet. 349:1997;1498-1504.
3. Michaud C.M., Murray C.J., Bloom B.R. Burden of disease - implications for future research. JAMA. 285:2001;535-539.
4. Pauwels R.A., Buist A.S., Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 163:2001;1256-1276.
5. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 343:2000;1902-1909.
6. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease a systematic review of randomized placebo-controlled trials . Am J Med. 113:2002;59-65.
7. Burge P.S., Calverley P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease the ISOLDE trial . BMJ. 320:2000;1297-1303.
8. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 152:(suppl):1995;S77- S121.
9. Sin D.D., Stafinski T., Ng Y.C., et al. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 165:2002;704-707.
10. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 272:1994;1497-1505.
11. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease a randomised controlled trial . Lancet. 361:2003;449-456.
12. Spencer S., Calverley P.M., Burge P.S., et al. Inhaled steroids in obstructive lung disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 163:2001;122-128.
13. Aaron S.D., Vandemheen K.L., Clinch J.J., et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest. 121:2002;688-696.
14. Paggiaro P.L., Dahle R., Bakran I., et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 351:1998;773-780.
15. McBride A, Milne R. Hospital-Based Pulmonary Rehabilitation Programmes For Patients with Severe Chronic Obstructive Pulmonary Disease. Southampton, United Kingdom: Wessex Institute for Health Research and Development; 1999. Development and Evaluation Committee Report No. 94.
16. United States Congress Office of Technology Assessment. Evaluation of the Oregon Medicaid Proposal. Washington, DC: U.S. Government Printing Office; 1992. Report No. OTA-H-531.
17. Vestbo J., Sorensen T., Lange P., et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease a randomised controlled trial . Lancet. 353:1999;1819-1823.
18. Niewoehner D.E., Erbland M.L., Deupree R.H., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 340:1999;1941-1947.
19. Alberta Health and Wellness. Medical Benefits Price List 2003. Available at: http://www.health.gov.ab.ca/professionals/SOMB/Price_List.pdf . Accessed October 8, 2003.
20. Alberta Health and Wellness Drug Benefit List 2003. Available at: http://www.ab.bluecross.ca/dbl/pdfs/ahwdbl_april_print.pdf . Accessed October 8, 2003.
21. Sin D.D., Tu J.V. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can Respir J. 7:2000;466-471.
22. Alberta Health and Wellness. Health Costing in Alberta: 2001 Annual Report. Available at: http://www.health.gov.ab.ca/public/document/ Health_Costing_2001.pdf . Accessed October 8, 2003.
23. Jackevicius C.A., Chapman K.R. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease a survey . Ann Pharmacother. 31:1997;160-164.
24. Statistics Canada. National Population Health Survey. Available at: http://www.statcan.ca/english/sdds/3225.htm . Accessed October 8, 2003.
25. Anthonisen N.R., Wright E.C., Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 133:1986;14-20.
26. Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 2nd ed. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
27. Chapman R.H., Stone P.W., Sandberg E.A., Bell C., Neumann P.J. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making. 20:2000;451-467.
28. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York, New York.
29. Cumming R.G., Mitchell P., Leeder S.R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 337:1997;8-14.
30. Baltzan M.A., Suissa S., Bauer D.C., Cummings S.R. Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group. Lancet. 353:1999;1327.
31. Lau E., Mamdani M., Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med. 114:2003;142-145.
32. Jones A., Fay J.K., Burr M., et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 1:2002;CD003537.
33. Delcourt C., Cristol J.P., Tessier F., et al. Risk factors for cortical, nuclear, and posterior subcapsular cataracts the POLA study. Pathologies Oculaires Liees a l'Age . Am J Epidemiol. 151:2000;497-504.
34. Calverley P.M. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 161:2000;341-342.
35. Barnes P.J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 161:2000;342-344.